Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Genzyme Therapeutics
4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, Oxfordshire, OX4 2SU
Telephone: +44 (0)1865 405 200
Fax: +44 (0)1865 774 172
WWW: http://www.genzyme.co.uk
Medical Information Direct Line: +44 (0)1483 505 515
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com
Customer Care direct line: +44 (0)1865 405 200
Medical Information Fax: +44(0)1483 554 805

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 23/05/2011
PIL MabCampath 30mg/ml concentrate for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to storage instructions
  • Change to side-effects
Updated on 05/01/2010 and displayed until 23/05/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 28/10/2009 and displayed until 05/01/2010
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
Updated on 02/06/2009 and displayed until 28/10/2009
Reasons for adding or updating:
  • Change to how the medicine works
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
Updated on 26/01/2009 and displayed until 02/06/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 27/08/2008 and displayed until 26/01/2009
Reasons for adding or updating:
  • Change to date of revision
  • Improved Electronic Presentation
Updated on 07/03/2008 and displayed until 27/08/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 29/01/2008 and displayed until 07/03/2008
Reasons for adding or updating:
  • Change to date of revision
Updated on 07/01/2008 and displayed until 29/01/2008
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to date of revision
Updated on 03/01/2008 and displayed until 07/01/2008
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to date of revision
Updated on 03/08/2007 and displayed until 03/01/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to name of manufacturer
Updated on 24/09/2006 and displayed until 03/08/2007
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to side-effects
  • Change to storage instructions
  • Change to date of revision
Updated on 12/12/2005 and displayed until 24/09/2006
Reasons for adding or updating:
  • Company name change or merger
Updated on 10/05/2005 and displayed until 12/12/2005
Reasons for adding or updating:
  • Change of trade or generic name
  • Change to date of revision
Updated on 10/02/2004 and displayed until 10/05/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 16/10/2002 and displayed until 10/02/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 20/02/2002 and displayed until 16/10/2002
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
  alemtuzumab